October Surprise: How Amgen’s Aflibercept Launch Shook Up US Biosimilars In 2024
As US Market Approaches Tenth Anniversary Of First Biosimilars Approval And Launch
As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024.
